TheEdgeResearch
Home / Stocks / RHY.AX

Rhythm Biosciences Limited (RHY.AX)

ASX Healthcare Medical - Diagnostics & Research
$0.08 ▼ -2.35%
Market Cap
$29.4M
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Beta
0.41
52-Wk Range
0.075-0.28
CEO
David Atkins
Country
AU
Currency
AUD

Rhythm Biosciences Limited operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Parkville, VIC, AU. The stock last traded at $0.08, down 2.35% on the session, giving a market capitalisation of $29.4M. Its beta of 0.41 implies it has historically moved less than the broad market.

Company profile
Exchange
Australian Securities Exchange
Employees
23
IPO date
2017-12-06
Headquarters
Parkville, VIC, AU
About Rhythm Biosciences Limited

Rhythm Biosciences Limited functions as a forward-thinking enterprise focused on predictive cancer diagnostics, active across both Australian and global territories. The company's core operations involve the creation, advancement, and market introduction of cutting-edge medical diagnostic technologies. A key innovation is ColoSTAT, their specialized blood test designed for the prompt and reliable identification of colorectal cancer. Established in 2017, the firm's main offices are located in Parkville, Australia.

Comparable companies

Rhythm Biosciences Limited is most often compared with the following Healthcare names:

AT1.AXBDX.AXENL.AXHMD.AXIDT.AXIIQ.AXIMC.AXMAP.AXNOX.AXOSL.AX
More research on RHY.AX
RHY.AX technical analysis RHY.AX TheEdge Score Compare against peers
Open full interactive analysis & DCF →